FinTechsDepot FinTechsDepot - Empowering FinTech Futures: Where Knowledge Fuels Innovation.

  • HOME
  • ARTICLES
    • Digital banking
  • RESOURCES
    • Whitepaper
    • Infographics
  • GLOBENEWSWIRE NEWS
  • EVENTS
    • Upcoming conference
    • Past Conference
    • Webinar
  • Contact Us
FinTechsDepot
  • Home
  • Admin
  • Page 29

Author

Admin 422 posts 0 comments

Whitepaper

FlashSpread cloud: The future of financial analysis

Admin Mar 18, 2025
Spreading tax returns is an essential task in commercial lending. As part of the process of standardizing…
Whitepaper

Composable Banking: Redefine Speed to Market

Admin Mar 17, 2025
In the modern era of on-demand consumption and tailored customer experiences, the ability to put together banking…
Whitepaper

The New Imperative for CFOs and CHROs

Admin Mar 14, 2025
With costs continuing to increase significantly influenced by many factors, managing escalating benefits costs…
Whitepaper

The rise of open banking consumer report

Admin Mar 13, 2025
Seldom is a whole landscape changed by a singular innovation, but when it happens, it’s undeniable. Online retail,…
Whitepaper

PSD2 and Open Banking Without Pain

Admin Mar 12, 2025
The European Union’s Second Payment Services Directive (PSD2) signaled a new era of change and innovation in the…
Past Conference

Achieving Financial Inclusion through the Cloud

Admin Mar 11, 2025
Over the past decade, cloud computing has revolutionized how people and organizations work around the world by…
Whitepaper

How to Measure the Financial Impact of Physical Risks

Admin Mar 11, 2025
Physical risks resulting from climate change can be acute (driven by an event such as a flood or storm) or chronic…
Whitepaper

Sage Intacct | Overcoming Financial Growing Pains in Professional Services…

Admin Mar 10, 2025
Overcome Financial Growing Pains to Drive Profitability Growing organizations face common challenges like…
Whitepaper

Maximising Financial Impact : Building the Business Case for Source-to-Pay

Admin Mar 7, 2025
Finance professionals face growing challenges in sourcing, procurement, and accounts payable (AP). Key obstacles…
Whitepaper

How Wealth and Asset management firms thrive with Sage Intacct

Admin Mar 6, 2025
Optimizing Financial Performance in Wealth & Asset Management with Sage Intacct Wealth and asset management…
Older Posts
Newer Posts

    SUBSCRIBE NOW


    Via Email
    Via Telephone


    I Agree. I would like to share my information with FinTechsDepot & their partners so that I can receive relevant information about products, services, & offers.

    RECENT POST

    • India’s Financial Revolution in 2026: How Digital Payments, Investments, and New Policies Are Reshaping the Economy
    • How to generate business growth with subscriptions
    • Understanding Banking Loans: A Comprehensive Guide
    • Understanding Credit Card Frauds: Types, Impact, and Prevention
    • Blackhawk Network Buys DIDIX Gifting & Promotions, a Dutch Company

    ARTICLE

    Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results
    2026-06-29T11:40:00Z
    - Recently closed $50 million underwritten offering reinforces strong institutional investor conviction and bolsters balance sheet for execution of second Phase 3 HLP003 trial1,2,3, EMBRACE, for potential U.S. FDA New...


    BrainsWay Presents Positive Data from Largest Real-World Study of Deep TMS™ in Patients with Comorbid PTSD and Major Depressive Disorder
    2026-06-29T11:30:00Z
    Nearly half of individuals diagnosed with PTSD also meet criteria for major depressive disorder (MDD), making comorbid depression one of the most common and clinically significant complications of PTSD


    Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer
    2026-06-29T11:30:00Z
    WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced...


    Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer
    2026-06-29T11:30:00Z
    Company expands executive team with strategic corporate affairs leader as it advances its differentiated obesity portfolio


    Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
    2026-06-29T11:30:00Z
    FDA’s rolling review process is intended to facilitate expedited review, enabling FDA to begin evaluating completed modules of the NDA before the full application is submitted


    Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)
    2026-06-29T11:25:29Z
    HORIZON is a potentially pivotal, randomized, double-blind, placebo-controlled Phase 2 study evaluating TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg as a first-line monotherapy in adults with MDD


    Dyadic Expands IP Protection and Business Development Activities in Japan
    2026-06-29T11:25:00Z
    Bolsters Japan Market Expansion, Strategic Collaborations and Demand for Scalable Recombinant Protein Solutions


    Zelluna ASA: Mandatory notification of trade – Return of lent shares following Private Placement
    2026-06-29T11:03:47Z
    Oslo, 29 June 2026: Reference is made to the stock exchange announcement by Zelluna ASA (the "Company") on 18 June 2026 regarding completion of a private placement of 3,143,958 new shares...


    George Medicines appoints Brendan Walsh as Senior Vice President of Supply Chain & Technical Operations
    2026-06-29T11:00:00Z
    London, UK, Boston, MA, 29 June 2026 – George Medicines, a late-stage biopharmaceutical company focused on addressing significant unmet needs in cardiometabolic disease, today announces the appointment of Brendan Walsh...


    Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes
    2026-06-29T11:00:00Z
    CORAL GABLES, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous...


    Sagimet Biosciences Joins the Russell 2000® and Russell 3000® Indexes
    2026-06-29T11:00:00Z
    SAN MATEO, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that...


    Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ET
    2026-06-29T11:00:00Z
    CAMBRIDGE, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the...


    Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy
    2026-06-29T11:00:00Z
    TORONTO, June 29, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat degenerative muscle diseases, today...


    Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis
    2026-06-29T11:00:00Z
    EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate claseprubart 300mg/2mL S.C. dosed Q2W and Q4W vs. placebo, with top-line results anticipated in 2H’28


    NetraMark Signs New NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company
    2026-06-29T11:00:00Z
    TORONTO, June 29, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence (AI) company that is transforming clinical trials...


    BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility
    2026-06-29T11:00:00Z
    —Advances strategic shift toward a disciplined research model prioritizing external innovation to accelerate rare disease pipeline growth—


    Conavi Medical Receives $1.25 Million Milestone Payment Under Ontario Life Sciences Scale-Up Fund
    2026-06-29T11:00:00Z
    Company has received $1.75 million in total under the program, including a $1.25 million payment triggered by the Company’s U.S. FDA clearance, to support the commercial launch of its hybrid...


    NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer
    2026-06-29T11:00:00Z
    ROCKVILLE, Md., June 29, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a clinical-stage biopharmaceutical company advancing innovative medicines for areas of significant unmet need, today...


    Dr. Mariusz Sapijaszko elected President of the Canadian Dermatology Association
    2026-06-29T11:00:00Z
    OTTAWA, Ontario, June 29, 2026 (GLOBE NEWSWIRE) -- The Canadian Dermatology Association (CDA) is pleased to announce the appointment of Dr. Mariusz Sapijaszko as CDA President, effective June 25, 2026.


    Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen
    2026-06-29T10:59:00Z
    CAMBRIDGE, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced it will present new data across its Alzheimer’s disease portfolio at the Alzheimer’s Association International Conference...


    Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia
    2026-06-29T10:30:00Z
    BALA CYNWYD, Pa., June 29, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced it...


    Zymeworks to Acquire Theravance Biopharma, Inc.
    2026-06-29T10:00:00Z
    VANCOUVER, British Columbia, June 29, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) (the “Company”), a biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline...


    Resalis Announces Initiation of Phase 1b Clinical Study Evaluating RES-010 as Treatment to Address Unmet Needs in Obesity
    2026-06-29T09:00:00Z
    Torino, Italy, June 29, 2026 – Resalis Therapeutics today announced the dosing of the first participant in a Phase 1b clinical study of its lead candidate, RES-010, a novel antisense...


    ITM, Helmholtz Munich and the University of Münster Announce Updated Preliminary Phase 1 Data with ITM-31 in Glioblastoma Patients
    2026-06-29T09:00:00Z
    Garching/Munich and Münster, Germany - June 29, 2026 - ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, Helmholtz Munich and the University of Münster today announced updated...


    Zelluna ASA: New share capital registered
    2026-06-29T07:59:20Z
    Oslo, Norway, 29 June 2026: Reference is made to the stock exchange announcement published by Zelluna ASA (the “Company”) on 18 June 2026 regarding a successfully placed private placement (the...


    Aplagon Appoints Carl Lindgren as Board Chair to Guide Later Stage Clinical and Corporate Development
    2026-06-29T07:00:00Z
    Veteran life sciences executive brings over 30 years of strategic and commercial leadership as Aplagon advances through Phase 2 development in multiple thrombosis-inflammatory diseases


    Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations
    2026-06-29T07:00:00Z
    MILAN and BRIDGEWATER, N.J., June 29, 2026 (GLOBE NEWSWIRE) -- Zambon and Amneal Pharmaceuticals today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive...


    Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
    2026-06-29T06:36:41Z
    COPENHAGEN, Denmark, June 29, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on June 2, 2026, under which the Company will repurchase shares...


    Zelluna ASA activates The Royal Marsden as second clinical site for ZIMA-101, expanding clinical execution capabilities
    2026-06-29T06:30:00Z
    Oslo, 29 June 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announced that The Royal...


    AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML
    2026-06-29T05:59:49Z
    PRESS RELEASE

    Copyright © 2026 | FinTechsDepot | All Rights Reserved |
    Privacy Policy | Unsubscribe
    Sign in

    Welcome, Login to your account.

    Forget password?
    Sign in

    Recover your password.

    A password will be e-mailed to you.